Deaths Prompt Warnings On Psoriasis Drug Raptiva

Law360, New York (February 19, 2009, 12:00 AM EST) -- Genentech Inc.'s psoriasis drug Raptiva came under attack Thursday on both sides of the Atlantic after reports that three patients using the drug died of a rare brain infection. Officials in the U.S. issued a public health advisory, while their counterparts in Europe recommended a halt to Raptiva sales.

The U.S. Food and Drug Administration said in a statement that it had confirmed that four people taking Raptiva contracted progressive multifocal leukoencephalopathy, a viral infection that damages the protective sheath surrounding nerves and usually leads to...
To view the full article, register now.